NTLA - インテリア・セラピュ―ティクス (Intellia Therapeutics Inc.) インテリア・セラピュ―ティクス

 NTLAのチャート


 NTLAの企業情報

symbol NTLA
会社名 Intellia Therapeutics Inc (インテリア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インテリア・セラピューティクス(Intellia Therapeutics Inc.)はゲノム編集会社である。同社はCRISPR/Cas9という生物学的ツールを利用した治療法の開発に従事する。CRISPR/Cas9ゲノム編集システムは2つの成分を含む。Cas9タンパク質は遺伝子のノックアウト・修復・挿入のための自然細胞修復プロセスを開始する分子ハサミのように働く。ガイドRNA配列はCas9を特定の標的デオキシリボ核酸(DNA)配列に認識し導く。同社のセンチネルインビボプログラムは、肝臓へのCRISPR/Cas9複合体の送達のための脂質ナノ粒子(LNP)の使用に焦点を当てる。同社の事業部であるeXtellia Therapeuticsは、免疫腫瘍学・自己免疫性疾患・炎症性疾患の分野におけるCRISPR / Cas9ゲノム編集の応用に従事する。同社の子会社はIntellia Securities Corpを含む。   インテリア・セラピュ―ティクスは米国のライフサイエンス企業。遺伝子改変技術に取り組み、ゲノム編集ツ―ルである「クリスパ―・キャス9(CRISPR/Cas9)」システムを利用し、トランスチレチン・アミロイド症やB型肝炎、アンチトリプシン欠乏症などの治療を可能にする。本社はマサチュ―セッツ州ケンブリッジ。   Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
本社所在地 40 Erie Street Suite 130 Cambridge MA 02139 USA
代表者氏名 Perry A. Karsen ペリーA.カーセン
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-285-6200
設立年月日 41760
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 195人
url www.intelliatx.com
nasdaq_url https://www.nasdaq.com/symbol/ntla
adr_tso
EBITDA EBITDA(百万ドル) -82.90700
終値(lastsale) 24.21
時価総額(marketcap) 1045887324.93
時価総額 時価総額(百万ドル) 958.62210
売上高 売上高(百万ドル) 29.13100
企業価値(EV) 企業価値(EV)(百万ドル) 653.08410
当期純利益 当期純利益(百万ドル) -82.89400
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Intellia Therapeutics Inc revenues increased 25% to $15.1M. Net loss increased 54% to $43.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 58% to $40.9M (expense) Stock-based Compensation in R&D increase of 64% to $5M (expense).

 NTLAのテクニカル分析


 NTLAのニュース

   Intellia Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference  2020/08/03 12:00:00 GlobeNewswire
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing…
   GEMoaB et Intellia Therapeutics concluent un accord de collaboration de recherche et d'octroi de licence concernant l'immunothérapie cellulaire nouvelle génération basée sur les plateformes propriétaires de modification localisée de séquence génomique RevCAR et CRISPR/Cas9  2020/07/21 04:26:00 PR Newswire
- GEMoaB et Intellia vont allier technologies exclusives et expertise en recherche et développement afin de créer des immunothérapies cellulaires allogènes transformatrices contre des cibles prometteuses dans des maladies oncologiques et inflammatoires - GEMoaB recevra des paiements…
   Intellia Therapeutics partners with GEMoaB to develop immunotherapies (NASDAQ:NTLA)  2020/07/20 12:54:00 Seeking Alpha
Intellia (NASDAQ:NTLA) announces a research collaboration with privately held GEMoaB, wherein the companies will combine GEMoaB's proprietary RevCAR techno
   GEMoaB und Intellia Therapeutics beschließen Forschungszusammenarbeit und Lizenzvereinbarung über zelluläre Immuntherapien der nächsten Generation auf Grundlage der patentrechtlich geschützten Technologie-Plattformen RevCAR und CRISPR/Cas9  2020/07/20 12:00:00 PR Newswire
GEMoaB und Intellia planen, ihre patentrechtlich geschützten Technologien und Forschungs- und Entwicklungsexpertise zu kombinieren, um bahnbrechende allogene zelluläre Immuntherapien für schwer behandelbare Erkrankungen in der Onkologie und bei Immunologischen Erkrankungen zu entwickeln…
   GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms  2020/07/20 12:00:00 PR Newswire
DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (Nasdaq:…
   GEMoaB et Intellia Therapeutics concluent un accord de collaboration de recherche et d'octroi de licence concernant l'immunothérapie cellulaire nouvelle génération basée sur les plateformes propriétaires de modification localisée de séquence génomique RevCAR et CRISPR/Cas9  2020/07/21 04:26:00 PR Newswire
- GEMoaB et Intellia vont allier technologies exclusives et expertise en recherche et développement afin de créer des immunothérapies cellulaires allogènes transformatrices contre des cibles prometteuses dans des maladies oncologiques et inflammatoires - GEMoaB recevra des paiements…
   Intellia Therapeutics partners with GEMoaB to develop immunotherapies (NASDAQ:NTLA)  2020/07/20 12:54:00 Seeking Alpha
Intellia (NASDAQ:NTLA) announces a research collaboration with privately held GEMoaB, wherein the companies will combine GEMoaB's proprietary RevCAR techno
   GEMoaB und Intellia Therapeutics beschließen Forschungszusammenarbeit und Lizenzvereinbarung über zelluläre Immuntherapien der nächsten Generation auf Grundlage der patentrechtlich geschützten Technologie-Plattformen RevCAR und CRISPR/Cas9  2020/07/20 12:00:00 PR Newswire
GEMoaB und Intellia planen, ihre patentrechtlich geschützten Technologien und Forschungs- und Entwicklungsexpertise zu kombinieren, um bahnbrechende allogene zelluläre Immuntherapien für schwer behandelbare Erkrankungen in der Onkologie und bei Immunologischen Erkrankungen zu entwickeln…
   GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms  2020/07/20 12:00:00 PR Newswire
DRESDEN, Germany, July 20, 2020 /PRNewswire/ -- GEMoaB, a biopharmaceutical company focused on the development of next-generation immunotherapies for hard-to-treat cancers, announced today that it has entered into a research collaboration and license agreement with Intellia (Nasdaq:…
   The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs  2020/07/10 11:25:13 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX ) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. (NYSE: BIOV ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCMV Dynavax Technologies Corporation (NASDAQ: DVAX ) Eli Lilly And Co (NYSE: LLY ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ITAMAR MED LTD/S ADR (NASDAQ: ITMR ) Meridian Bioscience, Inc. (NASDAQ: VIVO ) Nantkwest Inc (NASDAQ: NK ) NeoGenomics, Inc. (NASDAQ: NEO ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Penumbra Inc (NYSE: PEN ) Qiagen NV ( NYSE: QGEN ) Quidel Corporation (NASDAQ: QDEL ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Seattle Genetics, Inc. (NASDAQ: SGEN ) TG Therapeutics Inc (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 9) ANI Pharmaceuticals Inc (NASDAQ: ANIP ) Evolus Inc (NASDAQ: EOLS ) immatics biotechnologies GmbH (NASDAQ: IMTX ) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) Polypid Ltd (NASDAQ: PYPD ) Recro Pharma Inc (NASDAQ: REPH ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Ziopharm Announces Initiation of Phase 1 Trial For Blood Cancer Cell Therapy ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) said it has initiated a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing technology, or …
   The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive  2020/05/21 12:01:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on May 20.) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Ascendis Pharma A/S (NASDAQ: ASND ) (announced first-quarter results) Altimmune Inc (NASDAQ: ALT ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Cue Biopharma Inc (NASDAQ: CUE ) (reacted to first-quarter results) Evoke Pharma Inc (NASDAQ: EVOK ) (announced FDA's conditional approval for the brand name Gimoti for its nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis) GENMAB A/S/S ADR (NASDAQ: GMAB ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Novo Nordisk A/S (NYSE: NVO ) PDL BioPharma Inc (NASDAQ: PDLI ) Pulmatrix Inc (NASDAQ: PULM ) Qiagen NV (NYSE: QGEN ) Soleno Therapeutics Inc (NASDAQ: SLNO ) Surface Oncology Inc (NASDAQ: SURF ) - announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK ) VBI Vaccines Inc (NASDAQ: VBIV ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) (announced $20-million Series A financing to establish a Chinese joint venture) Down In The Dumps (Biotech stocks that hit 52-week lows on May 20.) Genfit SA (NASDAQ: GNFT ) RA Medical Systems Inc (NYSE: RMED ) (priced its 22.22-million-share common stock offering at 45 cents per share) Stocks In Focus Gilead-Galapagos Drug Produces Mixed Results In Ulcerative Colitis Study Gilead Sciences, Inc. (NASDAQ: GILD ) and GALAPAGOS NV/S ADR (NASDAQ: GLPG ) announced top-line results from the Phase 2b/3 trial evaluating the efficacy and safety of filgotinib in adult patients with moderately to severely active ulcerative colitis showing mixed results.
   The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test  2020/05/20 12:12:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) ChemoCentryx Inc (NASDAQ: CCXI ) Evoke Pharma Inc (NASDAQ: EVOK ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Translate Bio Inc (NASDAQ: TBIO ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) VBI Vaccines Inc (NASDAQ: VBIV ) Vermillion, Inc. (NASDAQ: VRML ) Zai Lab Ltd (NASDAQ: ZLAB ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 19) Lyra Therapeutics Inc (NASDAQ: LYRA ) (IPOed May 1) Stocks In Focus Myriad Announces FDA Approval For Companion Diagnostic Test For Prostate Cancer Myriad Genetics, Inc. (NASDAQ: MYGN ) said the FDA approved the BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza.
   The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering  2020/05/19 12:24:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 18) ADC Therapeutics SA (NYSE: ADCT ) (went public May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) AtriCure Inc. (NASDAQ: ATRC ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Evoke Pharma Inc (NASDAQ: EVOK ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Geron Corporation (NASDAQ: GERN ) Horizon Therapeutics PLC (NASDAQ: HZNP ) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Minerva Neurosciences Inc (NASDAQ: NERV ) Moderna Inc (NASDAQ: MRNA ) ( announced positive interim Phase 1 readout for coronavirus vaccine) Myokardia Inc (NASDAQ: MYOK ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Novavax, Inc. (NASDAQ: NVAX ) (reacted to upward price target adjustment by B.
   Global CRISPR Technology Markets to 2023 - Featuring Caribou Biosciences, Genscript & Intellia Therapeutics Among Others - ResearchAndMarkets.com  2020/05/19 10:25:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The scope of this report is broad, covering the applications of CRISPR in medicine, drug therapy and agriculture. The market for CRISPR technology is broken down by application and end user. Revenue forecasts from 2018-2023 are given for each end user category and application with estimated value derived from the revenue of the companies' total revenues. This report also
   Intellia Therapeutics Inc (NTLA) Reports Q1 Loss, Misses Revenue Estimates  2020/05/07 13:15:14 Zacks Investment Research
Intellia Therapeutics Inc (NTLA) delivered earnings and revenue surprises of -61.54% and -46.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インテリア・セラピュ―ティクス NTLA Intellia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)